Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 11-Sep-23 9:15 AM View:  | Hurvitz Chaim Director | Nrx Pharmaceuticals, Inc. (NRXP) | 30-Aug-23 | Private Purchase | 70,000 | $0.29 | $20,125.00 | 3% 2.14M to 2.21M | |
| 11-Sep-23 9:19 AM View: | Gorovitz Aaron Director | Nrx Pharmaceuticals, Inc. (NRXP) | 30-Aug-23 | Private Purchase | 35,000 | $0.32 | $11,196.50 | 50% 70.0K to 105.0K | |
| 24-Aug-23 12:14 PM View: | Javitt Jonathan C Chief Scientist Director 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 23-Aug-23 | Private Purchase | 100,000 | $0.33 | $33,000.00 | < 1% 14.67M to 14.77M | |
| 23-Aug-23 9:24 AM View: | Javitt Jonathan C Chief Scientist Director 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 22-Aug-23 | Private Purchase | 200,000 | $0.32 | $64,400.00 | 1% 14.47M to 14.67M | |
| 19-Dec-22 7:09 AM View: | van Voorhees Seth Chief Financial Officer | Nrx Pharmaceuticals, Inc. (NRXP) | 16-Dec-22 | Private Purchase | 30,000 | $1.10 | $33,000.00 | 184% 16.34K to 46.34K | |
| 19-Dec-22 7:14 AM View: | Willard Stephen H Chief Executive Officer Director | Nrx Pharmaceuticals, Inc. (NRXP) | 16-Dec-22 | Private Purchase | 50,000 | $1.17 | $58,500.00 | 100% 0 to 50.0K | |
| 14-Feb-23 10:00 PM View: | Javitt Jonathan C Director 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 14-Dec-22 | Gift | 300,000 | -- | -- | (2%) 14.77M to 14.47M | |
| 09-Dec-22 4:33 PM View: | Javitt Jonathan C Director 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 07-Dec-22 | Sale | 400,000 | $1.00 | $400,000.00 | (3%) 14.87M to 14.47M | |
| 01-Dec-22 7:29 PM View: | Javitt Daniel C. 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 30-Nov-22 | Sale (Planned) | 8,441 | $1.50 | $12,700.30 | (< 1%) 9.64M to 9.63M | |
| 01-Dec-22 7:29 PM View: | Javitt Daniel C. 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 29-Nov-22 | Sale (Planned) | 13,730 | $1.50 | $20,651.30 | (< 1%) 9.66M to 9.64M | |
| 29-Nov-22 7:00 AM View: | Flynn Patrick John Director | Nrx Pharmaceuticals, Inc. (NRXP) | 28-Nov-22 | Private Purchase | 10,000 | $1.25 | $12,475.00 | 7% 145.84K to 155.84K | |
| 29-Nov-22 7:00 AM View: | Flynn Patrick John Director | Nrx Pharmaceuticals, Inc. (NRXP) | 28-Nov-22 | Purchase | 1,750 | $1.25 | $2,187.50 | 1% 155.84K to 157.59K | |
| 28-Nov-22 7:42 AM View: | van Voorhees Seth Chief Financial Officer | Nrx Pharmaceuticals, Inc. (NRXP) | 25-Nov-22 | Private Purchase | 16,337 | $1.11 | $18,215.20 | 40842% 40 to 16.38K | |
| 21-Nov-22 5:58 PM View: | Hurvitz Chaim Director | Nrx Pharmaceuticals, Inc. (NRXP) | 18-Nov-22 | Purchase | 40,408 | $1.10 | $44,448.80 | 2% 2.1M to 2.14M | |
| 18-Nov-22 7:05 PM View: | Javitt Daniel C. 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 17-Nov-22 | Sale (Planned) | 33,018 | $1.05 | $34,744.80 | (< 1%) 9.69M to 9.66M | |
| 21-Nov-22 5:58 PM View: | Hurvitz Chaim Director | Nrx Pharmaceuticals, Inc. (NRXP) | 17-Nov-22 | Purchase | 171,780 | $1.08 | $185,522.00 | 9% 1.93M to 2.1M | |
| 21-Nov-22 5:58 PM View: | Hurvitz Chaim Director | Nrx Pharmaceuticals, Inc. (NRXP) | 16-Nov-22 | Private Purchase | 287,812 | $0.99 | $284,934.00 | 17% 1.64M to 1.93M | |
| 18-Nov-22 7:05 PM View: | Javitt Daniel C. 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 16-Nov-22 | Sale (Planned) | 133,719 | $1.02 | $136,393.00 | (1%) 9.82M to 9.69M | |
| 15-Nov-22 7:40 PM View: | Javitt Daniel C. 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 11-Nov-22 | Sale (Planned) | 49,200 | $1.01 | $49,510.00 | (< 1%) 9.87M to 9.82M | |
| 02-Aug-22 5:43 PM View: | Javitt Daniel C. 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 29-Jul-22 | Sale | 784,063 | $1.01 | $791,433.00 | (7%) 10.66M to 9.87M | |
| 05-Jul-22 5:06 PM View: | Javitt Daniel C. 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 01-Jul-22 | Gift | 2,000,000 | -- | -- | (16%) 12.66M to 10.66M | |
| 07-Jun-22 8:11 PM View: | Javitt Daniel C. 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 07-Jun-22 | Sale | 86,459 | $0.65 | $55,861.20 | (< 1%) 12.74M to 12.66M | |
| 07-Jun-22 8:11 PM View: | Javitt Daniel C. 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 06-Jun-22 | Sale | 115,657 | $0.67 | $76,946.60 | (< 1%) 12.86M to 12.74M | |
| 07-Jun-22 8:11 PM View: | Javitt Daniel C. 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 03-Jun-22 | Sale | 243,596 | $0.70 | $171,102.00 | (2%) 13.1M to 12.86M | |
| 02-Jun-22 8:55 AM View: | Javitt Jonathan C Chief Scientist Director 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 01-Jun-22 | Purchase | 100,000 | $58.00 | $5,800,000.00 | < 1% 14.77M to 14.87M | |
| 02-Nov-21 4:04 PM View: | Besthof Robert Chief Comm. & Patient Officer | Nrx Pharmaceuticals, Inc. (NRXP) | 15-Sep-21 | Market Option Sale | 40,000 | $11.76 | $470,400.00 | (63%) 63.71K to 23.71K | |
| 02-Nov-21 4:05 PM View: | Daigneault Alessandra General Counsel & Secretary | Nrx Pharmaceuticals, Inc. (NRXP) | 02-Sep-21 | Option Exercise | 31,584 | $3.07 | $96,962.90 | 100% 0 to 31.58K | |
| 02-Nov-21 4:07 PM View: | McMaster Herbert Raymond Director | Nrx Pharmaceuticals, Inc. (NRXP) | 26-Aug-21 | Option Exercise | 18,300 | $2.22 | $40,626.00 | 100% 0 to 18.3K | |
| 02-Nov-21 4:05 PM View: | Daigneault Alessandra General Counsel & Secretary | Nrx Pharmaceuticals, Inc. (NRXP) | 23-Aug-21 | Market Option Sale | 33,715 | $13.11 | $442,004.00 | (100%) 33.72K to 0 | |
| 02-Nov-21 4:05 PM View: | Daigneault Alessandra General Counsel & Secretary | Nrx Pharmaceuticals, Inc. (NRXP) | 19-Aug-21 | Option Exercise | 27,395 | $3.07 | $84,102.60 | 433% 6.32K to 33.72K | |
| 02-Nov-21 4:04 PM View: | Besthof Robert Chief Comm. & Patient Officer | Nrx Pharmaceuticals, Inc. (NRXP) | 16-Aug-21 | Option Exercise | 63,710 | $0.20 | $12,742.00 | 100% 0 to 63.71K | |
| 02-Nov-21 4:06 PM View: | Javitt Daniel C. 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 16-Jul-21 | Gift | 869,188 | -- | -- | (6%) 13.97M to 13.1M | |
| 10-Jun-21 6:47 PM View: | Hurvitz Chaim Director | Nrx Pharmaceuticals, Inc. (NRXP) | 24-May-21 | Grant | 1,644,790 | -- | -- | 100% 0 to 1.64M | |
| 10-Jun-21 6:48 PM View: | Javitt Jonathan C Chief Executive Officer Director 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 24-May-21 | Grant | 14,771,000 | -- | -- | 31881% 46.3K to 14.82M | |
| 10-Jun-21 6:46 PM View: | Flynn Patrick John Director | Nrx Pharmaceuticals, Inc. (NRXP) | 24-May-21 | Grant | 432,750 | -- | -- | 100% 0 to 432.75K | |
| 10-Jun-21 6:48 PM View: | Javitt Daniel C. 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 24-May-21 | Grant | 13,971,900 | -- | -- | 100% 0 to 13.97M | |
| 10-Jun-21 6:47 PM View: | Gorovitz Aaron Director | Nrx Pharmaceuticals, Inc. (NRXP) | 24-May-21 | Grant | 41,686 | -- | -- | 100% 0 to 41.69K | |
| 25-May-21 8:02 PM View: | Brac Lending Group LLC 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 24-May-21 | Disposition | 869,565 | -- | -- | (61%) 1.43M to 562.43K | |
| 25-May-21 9:17 PM View: | Big Rock Partners Sponsor, ... 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 24-May-21 | Conversion | 27,250 | -- | -- | 5% 497.5K to 524.75K | |
| 10-Jun-21 6:46 PM View: | Glied Sharon Director | Nrx Pharmaceuticals, Inc. (NRXP) | 24-May-21 | Grant | 13,168 | -- | -- | 100% 0 to 13.17K | |
| 10-Jun-21 6:48 PM View: | Javitt Jonathan C Chief Executive Officer Director 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 24-May-21 | Grant | 46,332 | -- | -- | 100% 0 to 46.33K | |
| 25-May-21 9:17 PM View: | Big Rock Partners Sponsor, ... 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 24-May-21 | Disposition | 5,435 | -- | -- | (1%) 524.75K to 519.32K | |
| 10-Jun-21 6:48 PM View: | Troy Daniel Director | Nrx Pharmaceuticals, Inc. (NRXP) | 24-May-21 | Grant | 43,093 | -- | -- | 100% 0 to 43.09K | |
| 10-Jun-21 6:45 PM View: | Daigneault Alessandra General Counsel & Secretary | Nrx Pharmaceuticals, Inc. (NRXP) | 24-May-21 | Grant | 6,320 | -- | -- | 100% 0 to 6.32K | |
| 17-Mar-20 4:37 PM View: | Polar Securities Inc. 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 13-Mar-20 | Market Sale | 29,464 | $10.60 | $312,318.00 | (6%) 517.5K to 488.04K | (106%) |
| 20-Nov-18 7:49 PM View: | Ackerman Richard President and CEO Director | Nrx Pharmaceuticals, Inc. (NRXP) | 20-Nov-18 | Sale | 1,500,000 | -- | -- | (75%) 2.0M to 497.5K | |
| 04-Dec-17 8:23 PM View: | Ackerman Richard President and CEO Director 10% Owner | Nrx Pharmaceuticals, Inc. (NRXP) | 29-Nov-17 | Purchase | 22,500 | $10.00 | $225,000.00 | 1% 1.98M to 2.0M |
